MX2021013910A - Metodos para administrar un anticuerpo anti-cd38 para tratar el mieloma multiple. - Google Patents

Metodos para administrar un anticuerpo anti-cd38 para tratar el mieloma multiple.

Info

Publication number
MX2021013910A
MX2021013910A MX2021013910A MX2021013910A MX2021013910A MX 2021013910 A MX2021013910 A MX 2021013910A MX 2021013910 A MX2021013910 A MX 2021013910A MX 2021013910 A MX2021013910 A MX 2021013910A MX 2021013910 A MX2021013910 A MX 2021013910A
Authority
MX
Mexico
Prior art keywords
antibody
administering
methods
multiple myeloma
treat multiple
Prior art date
Application number
MX2021013910A
Other languages
English (en)
Spanish (es)
Inventor
Heloise Audat
Zambrano Frank Campana
Sylvia Marion
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2021013910A publication Critical patent/MX2021013910A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2021013910A 2019-05-14 2020-05-13 Metodos para administrar un anticuerpo anti-cd38 para tratar el mieloma multiple. MX2021013910A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962847825P 2019-05-14 2019-05-14
US201962860739P 2019-06-12 2019-06-12
US201962899088P 2019-09-11 2019-09-11
EP20305223 2020-03-03
PCT/US2020/032754 WO2020232173A1 (en) 2019-05-14 2020-05-13 Methods of administering anti-cd38 antibody to treat multiple myeloma

Publications (1)

Publication Number Publication Date
MX2021013910A true MX2021013910A (es) 2022-03-11

Family

ID=71094805

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013910A MX2021013910A (es) 2019-05-14 2020-05-13 Metodos para administrar un anticuerpo anti-cd38 para tratar el mieloma multiple.

Country Status (15)

Country Link
US (1) US20210171650A1 (cg-RX-API-DMAC7.html)
EP (1) EP3969004A1 (cg-RX-API-DMAC7.html)
JP (2) JP7801132B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220008305A (cg-RX-API-DMAC7.html)
CN (2) CN120501855A (cg-RX-API-DMAC7.html)
AU (1) AU2020274169A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022503A2 (cg-RX-API-DMAC7.html)
CA (1) CA3140034A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021016606A2 (cg-RX-API-DMAC7.html)
IL (1) IL287832A (cg-RX-API-DMAC7.html)
MA (1) MA55967A (cg-RX-API-DMAC7.html)
MX (1) MX2021013910A (cg-RX-API-DMAC7.html)
SG (1) SG11202112513YA (cg-RX-API-DMAC7.html)
TW (1) TW202108624A (cg-RX-API-DMAC7.html)
WO (1) WO2020232173A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
BR112021000065A2 (pt) * 2018-07-10 2021-04-06 Sanofi Terapias de combinação contra câncer direcionando cd38 e tgf-beta
WO2020250033A1 (en) * 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Combination therapies using cd-38 antibodies
IL302640A (en) * 2020-11-03 2023-07-01 Sanofi Aventis Us Llc Use of isatuximab for the treatment of multiple myeloma
KR20240024047A (ko) 2021-04-08 2024-02-23 아티바 바이오테라퓨틱스, 인크. Nk 세포와 cd38 표적 항체를 이용한 암 치료 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
EP3313441B1 (en) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
IL285110B2 (en) * 2019-01-28 2025-11-01 Sanofi Sa Methods of treating multiple myeloma

Also Published As

Publication number Publication date
JP7801132B2 (ja) 2026-01-16
WO2020232173A1 (en) 2020-11-19
US20210171650A1 (en) 2021-06-10
TW202108624A (zh) 2021-03-01
EP3969004A1 (en) 2022-03-23
CN120501855A (zh) 2025-08-19
MA55967A (fr) 2022-03-23
CO2021016606A2 (es) 2022-04-29
CA3140034A1 (en) 2020-11-19
AU2020274169A1 (en) 2022-01-20
JP2025166108A (ja) 2025-11-05
SG11202112513YA (en) 2021-12-30
JP2022532356A (ja) 2022-07-14
IL287832A (en) 2022-01-01
CN114080233A (zh) 2022-02-22
BR112021022503A2 (pt) 2021-12-28
KR20220008305A (ko) 2022-01-20

Similar Documents

Publication Publication Date Title
CO2021016606A2 (es) Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2021001083A (es) Regimen posologico para anticuerpos biespecificos contra bcma-cd3.
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
MX2022015499A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
AR105027A1 (es) Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos
CO2020008561A2 (es) Dosificación subcutánea de anticuerpos anti-cd38
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
FI3773715T3 (fi) Mirikitsumabi haavaisen paksusuolitulehduksen hoitamisessa
AR120399A1 (es) Un método de tratamiento de un cáncer positivo para dll3
JP2012131811A5 (cg-RX-API-DMAC7.html)
AR104771A1 (es) Inhalador de polvo seco
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
ZA202103820B (en) Capsule formulations
AR119430A1 (es) Métodos para tratar o prevenir la atrofia muscular espinal
AR111491A1 (es) Métodos para tratar enfermedades pediátricas
JOP20250118A1 (ar) الأجسام المضادة المضادة لببتيد بيتا النشواني N3pGlu وجرعاتها واستخداماتها
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
AR062779A1 (es) Tratamiento de la esclerosis multiple (em)
AR102903A1 (es) Inhalador de polvo seco
AR118933A1 (es) Dosificación del inhibidor de kras para el tratamiento de cánceres
CO2025001817A2 (es) Método para tratar una enfermedad mediada por linfocitos t
AR125403A1 (es) Métodos para el tratamiento de cánceres
AR130444A1 (es) Métodos para el tratamiento de infecciones virales
AR127614A1 (es) Métodos de tratamiento del glioblastoma